BAM
ALNY icon

Bruderman Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bruderman Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-84
Closed -$6K – 637
2018
Q4 		$6K Buy
84
+10
+14% +$769 ﹤0.01% 467
2018
Q3 		$6K Hold
74
– – ﹤0.01% 298
2018
Q2 		$7K Hold
74
– – ﹤0.01% 314
2018
Q1 		$9K Buy
+74
New +$9.54K ﹤0.01% 299

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Bruderman Asset Management's ALNY Position: Q1 2019 in Review

Bruderman Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2019, closing a stake of 84 shares — an estimated $6K sold.

Bruderman Asset Management first reported a position in ALNY in Q1 2018 and held it in 4 quarters. The position peaked at $9K in Q1 2018. 291 funds tracked by Wall St. Rank hold ALNY as of Q1 2019.

  • Bruderman Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Bruderman Asset Management sold 84 Alnylam Pharmaceuticals shares in Q1 2019, an estimated $6K.
  • Bruderman Asset Management first reported a position in Alnylam Pharmaceuticals in Q1 2018 and held it in 4 quarters.
  • Bruderman Asset Management's Alnylam Pharmaceuticals position peaked at $9K in Q1 2018.
  • 291 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2019.

Based on Bruderman Asset Management's 13F filing for Q1 2019, filed 14 May 2019.